About ASYMCHEM Company

The company (stock code: 002821.SZ/6821.HK) is a world-leading CDMO company, providing high-quality one-stop services for R&D and production of new drugs worldwide. It is our mission to accelerate the launch of new drugs and extend the quality of life. Relying on continuous technological innovation, we provide domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services for the full life cycle of drugs to accelerate the development and application of new drugs. The company is a world-leading, technology-driven CDMO one-stop integrated service provider. Accelerate clinical research and commercial application of innovative drugs by providing domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services for the full life cycle of drugs and efficient and high-quality R&D and production services. By providing domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services for the full life cycle of pharmaceuticals, efficient and high-quality R&D and production services in 2019, the company won the “2018 Best Partner for the Transformation and Upgrading of Chinese Pharmaceutical Enterprises”. A total of 6 winning enterprises/institutions were selected in this selection. As the only pharmaceutical CDMO company on the list, the company won the award through a hierarchical screening process for its excellent quality and service, good reputation and reputation - this is another time the company won this honor. It won the “China Pharmaceutical Industry Top 100” and “Top 20 Pharmaceutical Outsourcing Companies in China” awards in the “2018 China Pharmaceutical Industry Most Influential List” issued by the Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce, fully demonstrating the company's strong competitiveness and strong growth as an industry benchmark.